이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

미국에서 진행되는 파일럿 인체 조사로서, 2형 당뇨병 환자에서 근위부 장 점막 절제를 위한 무선주파수 증기 절제 시스템의 안전성, 내약성 및 효과를 평가하는 연구 (RESTORE-1 연구) (RESTORE-1)

2026년 9월 21일 업데이트: Aqua Medical, Inc.

제2형 당뇨병 환자의 근위부 장 점막 절제를 위한 무선 주파수 증기 절제 시스템의 안전성, 내약성 및 유효성 평가를 위한 미국 파일럿 인체 연구 (RESTORE-1 연구)

The purpose of this study is to assess the safety, tolerability and effectiveness of RF vapor ablation of the proximal intestinal mucosa. This study will test the hypothesis that RF vapor ablation will result in improvement in glycemic parameters, without Serious Adverse Events (SAE) or Unanticipated Adverse Device Effects (UADE).

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

The main aims of the study are :

Evaluate the safety of the device and procedure based on the reported adverse events that occur.

Evaluate device tolerability based on pain scores reported by patients. Evaluate the effectiveness of the device and procedure by comparing change in HbA1c from baseline to 168 days post procedure.

The subject population for this study are adults (22-65 years of age) with type-2 diabetes mellitus. Study participation is 6 months for each patient.

The study is comprised of 5 phases: Screening, Run-in, Pre-procedure tests, RF Vapor ablation procedure, and Post-vapor ablation follow-up (up to 168 days).

연구 유형

중재적

등록 (추정된)

20

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Arizona
      • Scottsdale, Arizona, 미국, 85258
        • 모병
        • HonorHealth Research Institute
        • 수석 연구원:
          • James Swain, MD
        • 연락하다:
      • Scottsdale, Arizona, 미국, 85054
        • 모병
        • Mayo Clinic
        • 수석 연구원:
          • Rahul Pannala, MD
        • 연락하다:
    • California
      • Newport Beach, California, 미국, 92663
        • 모병
        • Hoag Memorial Hospital Presbyterian
        • 수석 연구원:
          • Jennifer Phan, MD
        • 연락하다:
    • North Carolina
      • Chapel Hill, North Carolina, 미국, 27599
        • 모병
        • University of North Carolina School of Medicine
        • 수석 연구원:
          • Nicholas J Shaheen, MD, MPH
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

22년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Men and non-pregnant women 22-65 years of age

  2. Diagnosed with T2DM for at least 1 year and less than or equal to 15 years

  3. HbA1C of 7.5 - 10% (58-86 mmol/mol)

  4. BMI ≥ 24 and ≤ 40 kg/m2

  5. On one or more non-insulin glucose-lowering medications, with no therapeutic changes in medication regimen for at least 12 weeks prior to the screening visit, to ensure stable glycemic control.

    Note 1: Exception for sulfonylureas (SU): For safety reasons, subjects taking sulfonylureas (limited to glipizide or glimepiride only) will be required to undergo a protocol-mandated reduction to ≤50% of the maximum labeled dose during the run-in phase. This adjustment is intended solely to minimize the risk of hypoglycemia during intensive monitoring and dietary standardization and will not be considered a therapeutic change for purposes of eligibility. Subjects unwilling to comply with this dose reduction will be excluded.

    Note 2: GLP-1s are considered non-insulin glucose lowering medications.

  6. Agrees to use an additional glucose-lowering treatment (e.g., liraglutide, other OAD except for glyburide), if recommended by the study Investigator in case of persistent hyperglycemia.

  7. Weight stability (defined as a < 5% change in body weight) in the 12 weeks prior to the screening visit. Participants should agree to refrain from using over the counter or herbal supplements intended for weight loss. Participants already on a prescribed weight loss drug should agree to not further titrate their medications during the study.

  8. Women of childbearing potential must be using at least one acceptable method of contraception throughout the study

  9. Willing and able to use CGM for the duration of the study and comply with study visits and study tasks as required per protocol.

  10. Able to comply with study requirements and understand and sign the Informed Consent Form

Exclusion Criteria:

  1. Diagnosis of Type-1 Diabetes
  2. History of diabetic ketoacidosis or hyperosmolar nonketotic coma.
  3. Probable insulin production failure, defined as serum C-peptide of 0.3-0.6 nmol/l.
  4. Current or previous use of any types of insulin for >1 month (at any time, except for treatment of gestational diabetes) in the last 2 years.
  5. Hypoglycemia unawareness as defined by a score of 4 or higher on a Gold score questionnaire suggestive of impaired awareness of hypoglycemia (IAH).
  6. History of severe hypoglycemia (2 or more severe hypoglycemic event, as defined by need for third-party assistance, in the last 6 months from the screening visit).
  7. Subjects with untreated or unstable microvascular complications of diabetes such as retinopathy, nephropathy, and neuropathy. Subjects who have been appropriately treated/monitored and stable for the prior 3 months before study participation can be included as determined as safe and reasonable by the study PI.
  8. Known systemic autoimmune disease that is uncontrolled or requiring steroids or biologics, including a positive anti-glutamic acid decarboxylase (GAD) test. Systemic autoimmune diseases include but not limited to celiac disease, duodenal Crohn disease or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other systemic autoimmune connective tissue disorder. (Participants with adequately controlled primary hypothyroidism or with mild to moderate psoriasis managed with topical therapy-affecting less than 10% of body surface area and not involving special areas (e.g., face, palms)-may be included).
  9. Previous GI surgery that could limit access to the duodenum such as Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions. (Patients who have undergone a laparoscopic sleeve gastrectomy (LSG) or an endoscopic sleeve gastrectomy (ESG) procedure more than one year prior to enrollment will not be excluded from participation in this study.)
  10. History of chronic pancreatitis or a diagnosis of idiopathic acute pancreatitis within the past 12 months.
  11. Documented history of diabetic gastroparesis confirmed by gastric emptying study.
  12. Known active hepatitis or liver disease, excluding nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
  13. Symptomatic gallstones, or acute gastrointestinal illness in the previous 7 days.
  14. Known history of severe irritable bowel syndrome, radiation enteritis or other inflammatory bowel syndrome, such as Crohn's disease and Celiac disease.
  15. Alcoholic liver disease, as indicated by ANI>-0.66 and AUDIT-C questionnaire
  16. Known history of a structural or functional esophageal disorder that could impede endoscope passage or elevate the risk of esophageal injury during an endoscopic procedure, including but not limited to moderate-severe (Los Angeles Grade C or D) esophagitis, dysphagia due to achalasia or stricture/stenosis, esophageal varices greater than Grade 2, history of esophageal perforation, or any other clinically significant esophageal condition.
  17. Presence of upper gastrointestinal conditions, including active ulcers, varices, strictures, congenital or acquired proximal intestinal telangiectasia, active H. pylori infection.
  18. Current use of anticoagulation therapy (vitamin K antagonists, such as warfarin, or current use of direct-action oral anticoagulants (DOACs) that cannot be safely discontinued peri procedurally
  19. Current use of P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued for 7 days before and 7 days after the procedure.
  20. Unable to discontinue high-dose non-steroidal anti-inflammatory drugs (NSAIDs) during treatment through 4 weeks following the procedure. Use of acetaminophen and low dose aspirin, PRN over the counter NSAIDs is allowed.
  21. Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 12 weeks prior to the baseline visit.
  22. Persistent anemia, defined as hemoglobin <10 g/dl on two consecutive measurements >6 weeks apart.
  23. Known history of hemoglobinopathy.
  24. Known history of blood donation or transfusion within 3 months prior or screening or anticipated blood donation during the study period.
  25. Significant cardiovascular disease, including known history of valvular heart disease, or myocardial infarction, heart failure, transient ischemic attack, or stroke within 12 months prior to the Screening Visit.
  26. Mean of 3 separate blood pressure measurements >180 mmHg (systolic) or >100 mmHg (diastolic).
  27. Estimated glomerular filtration rate (eGFR) ≤ 45 ml/min/1.73m2 (estimated by MDRD).
  28. Known immunocompromised status, including but not limited to: individuals who have undergone organ transplantation, receipt of chemotherapy, or radiotherapy within the past 12 months, clinically significant leukopenia, confirmed human immunodeficiency virus (HIV) infection, or any other condition impacting immune function that, in the opinion of the investigator, renders the participant unsuitable for trial participation.
  29. History of secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value >1.5x of the upper limit of normal range at screening)
  30. In the opinion of the Investigator, the participant is not an appropriate candidate for upper GI endoscopy or general anesthesia.
  31. Active illicit substance abuse or Alcohol Use Disorder (AUD) (consuming more than 14 drinks per week for men or more than seven drinks per week for women)
  32. Active malignancy within the last 5 years (excluding non-melanoma skin cancers)
  33. Women who are currently breastfeeding
  34. Participating in another ongoing clinical trial of an investigational drug or device.
  35. Any other physical or mental condition that, in the opinion of the investigator, would make the participant an unsuitable candidate for clinical trial participation.
  36. Critically ill or has a life expectancy <3 years.
  37. Use of a cardiac pacemaker, implantable cardioverter-defibrillator (AICD), duodenal metallic implants, or any other implanted electronic medical devices.
  38. General contraindications to deep or conscious sedation, general anesthesia, or upper gastrointestinal (GI) endoscopy, including individuals deemed high-risk by an anesthesiologist (e.g., ASA Physical Status Classification of IV or higher).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Study arm- RF Vapor Ablation arm (PIMA arm)

This is a single arm study. All enrolled patients will be included in this arm

RF Vapor ablation of the proximal intestinal mucosa

다른 이름들:
  • 아쿠아 메디컬 RF 베이퍼 시스템

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Safety endpoint
기간: 6 months

Number of subjects with reported device or procedure related SAEs or UADEs.

6 months
Tolerability endpoint
기간: 14 days

Descriptive statistics on Visual Analogue Scale(VAS) pain scores (A Visual Analog Scale (VAS) pain score is a patient's self-reported measure of pain intensity, marked on a straight line scale from 0-10, with "no pain" at the zero-end and "worst imaginable pain" at 10.)

14 days
Efficacy endpoint
기간: 6 months

Change in HbA1c from baseline to 6 months post procedure

6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Change in HbA1c at 3 months post procedure
기간: 3 months

Change in HbA1c (from baseline) at 3 months post procedure will be analyzed

3 months
Change in FPG from baseline to 3 months and 6 months post procedure
기간: 6 months

Change in Fasting Plasma Glucose from baseline to 3 months and 6 months post procedure

6 months
Proportion of ablation-treated subjects with an HbA1c improvement > 0.5% from baseline at 6 months.
기간: 6 months

Proportion of ablation-treated subjects with an HbA1c improvement > 0.5% from baseline at 6 months.

6 months
Change in HOMA-IR from baseline to 6 months post procedure.
기간: 6 months

Change in HOMA-IR from baseline to 6 months post procedure.

6 months
Change in UACR from baseline to 6 months post procedure.
기간: 6 months

Change in Urine Albumin-Creatinine Ratio from baseline to 6 months post procedure.

6 months
Change in ALT and AST from baseline to 6 months post procedure.
기간: 6 months

Change in ALT and AST from baseline to 6 months post procedure.

6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Nicholas Shaheen, MD, University of North Carolina

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 1일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2027년 3월 31일

연구 등록 날짜

최초 제출

2026년 1월 20일

QC 기준을 충족하는 최초 제출

2026년 1월 20일

처음 게시됨 (실제)

2026년 1월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 21일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CLD-1021-US

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be shared with other researchers.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .